Cromolyn

Summary

Cromolyn (CHEMBL428880) is an approved small-molecule calcium channel blocker (ATC R03BC01) targeting TAS2R7 and TAS2R20; indicated across 11 conditions including eye allergy and obstructive lung disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R03BC01 (+6 more)
• Targets: 2 (TAS2R7, TAS2R20)
• Indications: 11 conditions
• Clinical trials: 5
• Chemistry: 468.4 Da · C23H16O11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL428880
Name	Cromolyn
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	2882
ChEBI	CHEBI:59773
ATC	R03BC01, R01AC01, A07EB01, D11AH03, R01AC51, S01GX01, S01GX51
Molecular formula	C23H16O11
Molecular weight	468.4
InChIKey	IMZMKUWMOSJXDT-UHFFFAOYSA-N

SMILES: C1=CC2=C(C(=C1)OCC(COC3=CC=CC4=C3C(=O)C=C(O4)C(=O)O)O)C(=O)C=C(O2)C(=O)O

IUPAC name: 5-[3-(2-carboxy-4-oxochromen-5-yl)oxy-2-hydroxypropoxy]-4-oxochromene-2-carboxylic acid

ChEBI definition: A dicarboxylic acid that is the bis-chromone derivative of glycerol. It is effective as a mast cell stabilizer.

Pharmacological roles (ChEBI): calcium channel blocker, anti-asthmatic drug.

Also known as: Acide cromoglicique, Acido cromoglicico, Cromo-comod, Cromoglicate, Cromoglicic acid, Cromoglycate, Cromolyn, R03BC01, SID29215502, SID104171394, SID26751521, SID50103871

Parent form; salt/anhydrous children: CHEMBL74, CHEMBL351631, CHEMBL4797821

Patent coverage: 4,279 distinct patent families (14,789 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 13,292 (90%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
TAS2R7	TAS2R7	Agonist	2.35	0.2%	Q9NYW3
TAS2R20	TAS2R20	Agonist	4.35	0.1%	P59543

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Prelamin-A/C, G-protein coupled receptor 35, G-protein coupled receptor 35.

Bioactivity

ChEMBL activities: 11 potent at pChembl ≥ 5 of 12 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
GPR35	7.28	EC50	52	nM	CHEMBL_ACT_18198037
GPR35	6.68	EC50	210	nM	CHEMBL_ACT_13445759
GPR35	6.28	EC50	520	nM	CHEMBL_ACT_13445764
GPR35	6.28	EC50	520	nM	CHEMBL_ACT_25094456
LMNA	6.15	Potency	707.9	nM	CHEMBL_ACT_3649249
TDP1	5.75	Potency	1778	nM	CHEMBL_ACT_3928003
GPR35	5.63	Ki	2340	nM	CHEMBL_ACT_13445744
GPR35	5.53	Ki	2970	nM	CHEMBL_ACT_25094444
GPR35	5.16	EC50	7000	nM	CHEMBL_ACT_18198032
GPR35	5.16	EC50	7000	nM	CHEMBL_ACT_25094458
GPR35	5.1	EC50	8000	nM	CHEMBL_ACT_25497098

Target pathways

Aggregated over 2 target gene(s): TAS2R7, TAS2R20.

Top Reactome pathways

9 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	2	TAS2R20, TAS2R7
Signaling by GPCR	2	TAS2R20, TAS2R7
GPCR downstream signalling	2	TAS2R20, TAS2R7
G alpha (i) signalling events	2	TAS2R20, TAS2R7
Class C/3 (Metabotropic glutamate/pheromone receptors)	2	TAS2R20, TAS2R7
GPCR ligand binding	2	TAS2R20, TAS2R7
Sensory Perception	2	TAS2R20, TAS2R7
Sensory perception of taste	2	TAS2R20, TAS2R7
Sensory perception of sweet, bitter, and umami (glutamate) taste	2	TAS2R20, TAS2R7

Dominant GO biological processes

GO term	Targets
detection of chemical stimulus involved in sensory perception of bitter taste	2
signal transduction	2
G protein-coupled receptor signaling pathway	2
sensory perception of taste	2

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
eye allergy	4	MONDO:0005551	EFO:0005751
obstructive lung disease	4	MONDO:0002267	HP:0006536

6 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
stroke disorder	3	MONDO:0005098	EFO:0000712
psoriasis	2	MONDO:0005083	EFO:0000676
mastocytosis	2	MONDO:0007950	EFO:0009001
amyotrophic lateral sclerosis	2	MONDO:0004976	MONDO:0004976
Alzheimer disease	1	MONDO:0004975	MONDO:0004975
schizoaffective disorder	1	MONDO:0005487	EFO:0005411

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE2	3
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01175525	PHASE3	UNKNOWN	Treatment of Acute Stroke With Cromolyn(Single Dose)
NCT03794076	PHASE1/PHASE2	RECRUITING	Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia
NCT01701843	PHASE2	TERMINATED	Cromoglicate in Mastocytosis
NCT01722812	PHASE2	COMPLETED	Cromoglicate in Psoriasis
NCT03202147	PHASE2	WITHDRAWN	Safety and Efficacy of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

1 molecules share ≥1 primary target. Top 1 by shared-target count:

Molecule	Source	Status	Shared targets
ISOPROTERENOL	ChEMBL	Phase 4 (approved)	TAS2R20, TAS2R7